MX2014010278A - Variantes de albumina. - Google Patents

Variantes de albumina.

Info

Publication number
MX2014010278A
MX2014010278A MX2014010278A MX2014010278A MX2014010278A MX 2014010278 A MX2014010278 A MX 2014010278A MX 2014010278 A MX2014010278 A MX 2014010278A MX 2014010278 A MX2014010278 A MX 2014010278A MX 2014010278 A MX2014010278 A MX 2014010278A
Authority
MX
Mexico
Prior art keywords
variants
albumin variants
relates
present
parent albumin
Prior art date
Application number
MX2014010278A
Other languages
English (en)
Spanish (es)
Inventor
Karen Ann Delahay
Original Assignee
Novozymes Biopharma Dk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/058206 external-priority patent/WO2012150319A1/en
Application filed by Novozymes Biopharma Dk As filed Critical Novozymes Biopharma Dk As
Publication of MX2014010278A publication Critical patent/MX2014010278A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2014010278A 2012-03-16 2013-03-15 Variantes de albumina. MX2014010278A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP12160007 2012-03-16
PCT/EP2012/058206 WO2012150319A1 (en) 2011-05-05 2012-05-04 Albumin variants
EP12187326 2012-10-05
EP12191086 2012-11-02
EP12191854 2012-11-08
PCT/EP2013/055487 WO2013135896A1 (en) 2012-03-16 2013-03-15 Albumin variants

Publications (1)

Publication Number Publication Date
MX2014010278A true MX2014010278A (es) 2015-03-05

Family

ID=49160283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010278A MX2014010278A (es) 2012-03-16 2013-03-15 Variantes de albumina.

Country Status (14)

Country Link
US (3) US9944691B2 (enExample)
EP (2) EP3330283A3 (enExample)
JP (2) JP6441682B2 (enExample)
KR (1) KR20140136934A (enExample)
CN (1) CN104736559B (enExample)
AU (2) AU2013234299B2 (enExample)
BR (1) BR112014018679A2 (enExample)
CA (1) CA2861592A1 (enExample)
DK (1) DK2825556T3 (enExample)
ES (1) ES2664328T3 (enExample)
IL (1) IL233689A0 (enExample)
MX (1) MX2014010278A (enExample)
PL (1) PL2825556T3 (enExample)
WO (1) WO2013135896A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
AU2014217831A1 (en) 2013-02-16 2015-07-16 Albumedix Ltd. Pharmacokinetic animal model
EP3063171B1 (en) 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
PL3283524T3 (pl) 2015-04-17 2023-06-12 Amgen Research (Munich) Gmbh Konstrukty biswoistego przeciwciała dla cdh3 i cd3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
BR112018003179A2 (pt) * 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
JP7146637B2 (ja) 2015-12-22 2022-10-04 アルブミディクス リミティド 改善されたタンパク質発現株
WO2017112847A1 (en) 2015-12-22 2017-06-29 Albumedix A/S Improved protein expression strains
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
AR107582A1 (es) 2016-02-03 2018-05-16 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
US20200317749A1 (en) * 2016-07-01 2020-10-08 Denali Therapeutics Inc. Albumin variants for enhanced serum half-life
WO2018082758A1 (en) 2016-11-04 2018-05-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
WO2018096396A1 (en) * 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
EP4026908A1 (en) 2017-06-20 2022-07-13 Albumedix Ltd Improved protein expression strains
DK3641800T5 (da) 2017-06-22 2024-08-26 CSL Behring Lengnau AG Modulation af fviii immunogenicitet ved trunkeret vwf
CN118126157A (zh) 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
BR112021002032A2 (pt) 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
HUE068401T2 (hu) 2019-11-11 2024-12-28 Amgen Res Munich Gmbh A BCMA elleni hatóanyagok adagolási rendje
EP4069200A1 (en) 2019-12-04 2022-10-12 Albumedix Ltd Methods and compositions produced thereby
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
WO2021236638A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
TW202225188A (zh) 2020-11-06 2022-07-01 德商安美基研究（慕尼黑）公司 與ｃｄ３結合的多肽構建體
EP4240770A1 (en) 2020-11-06 2023-09-13 Amgen Research (Munich) GmbH Polypeptide constructs selectively binding to cldn6 and cd3
AU2021373318A1 (en) 2020-11-06 2023-05-25 Amgen Inc. Antigen binding domain with reduced clipping rate
US20250136704A1 (en) 2020-11-10 2025-05-01 Amgen Inc. Methods for administering a bcmaxcd3 binding molecule
US12599625B2 (en) 2021-05-13 2026-04-14 Penland Foundation Treatment of ARDS and other conditions caused by acutely elevated cytokine levels and post ARDS chronic cytokine production using inhaled anesthetics
WO2023287726A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of cancer using botulinum toxin and nitrous oxide
EP4598958A1 (en) 2022-10-05 2025-08-13 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
EP4608448A1 (en) 2022-10-28 2025-09-03 Aarhus Universitet Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response
EP4651904A1 (en) 2023-01-18 2025-11-26 Lycia Therapeutics, Inc. Lysosomal targeting bifunctional molecules for degradation of autoantibodies
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
EP4688851A1 (en) 2023-03-27 2026-02-11 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
CN121866074A (zh) 2023-08-09 2026-04-14 利西亚治疗公司 用于降解肌肉特异性激酶自身抗体的溶酶体靶向双官能分子
WO2025158071A1 (en) 2024-01-26 2025-07-31 Sartorius Albumedix Limited Retroviral preparations containing albumin for enhancing transduction efficiency, uses thereof for cell transduction
TW202602932A (zh) 2024-03-28 2026-01-16 美商萊西亞醫療公司 用於降解甲狀腺刺激荷爾蒙受體自體抗體之胞溶體靶向雙功能分子
TW202602940A (zh) 2024-04-09 2026-01-16 美商安進公司 激動性抗ｉｌ－２ｒｂｇ重鏈抗體
US20260092096A1 (en) 2024-05-14 2026-04-02 35Pharma Inc. Activin receptor type iib variants and uses thereof
EP4703468A1 (en) 2024-08-29 2026-03-04 Sartorius Albumedix Limited Methods and uses
WO2026074121A1 (en) 2024-10-02 2026-04-09 Sartorius Albumedix Limited Albumin formulations and uses thereof
CN121971639A (zh) * 2024-10-31 2026-05-05 翔安创新实验室 用于治疗泌尿系统疾病的药物
CN120192399B (zh) * 2025-05-27 2025-08-15 上海欣瑞特生物医药技术有限公司 一种猫血清白蛋白及其应用

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625041A (en) 1990-09-12 1997-04-29 Delta Biotechnology Limited Purification of proteins
US2714586A (en) 1951-06-25 1955-08-02 Phillips Petroleum Co Washing urea and thiourea containing adducts
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
JPS60169498A (ja) 1984-02-10 1985-09-02 Kyowa Hakko Kogyo Co Ltd 成人ｔ細胞白血病ウイルス抗原ペプチド誘導体
MX9203440A (es) 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
ES2052712T3 (es) 1987-04-09 1994-07-16 Delta Biotechnology Ltd Vector de levadura.
EP0305216B1 (en) 1987-08-28 1995-08-02 Novo Nordisk A/S Recombinant Humicola lipase and process for the production of recombinant humicola lipases
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
IL88326A (en) 1987-11-18 1993-03-15 Gist Brocades Nv Purification of serum albumin
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE4000939A1 (de) 1990-01-15 1991-07-18 Brem Gottfried Prof Dr Dr Verfahren zur antikoerpergewinnung
JP3230091B2 (ja) 1990-06-25 2001-11-19 ウェルファイド株式会社 ヒト血清アルブミンの着色抑制方法
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE4244915C2 (de) 1992-08-14 1998-12-03 Widmar Prof Dr Tanner DNA-Moleküle codierend Proteine, die an der O-Glykosylierung von Proteinen beteiligt sind
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
WO1995003402A1 (en) 1993-07-22 1995-02-02 Merck & Co., Inc. EXPRESSION OF HUMAN INTERLEUKIN-1β IN A TRANSGENIC ANIMAL
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
CN1230997A (zh) 1996-07-17 1999-10-06 津莫吉尼蒂克斯公司 甲醇毕赤酵母的转化
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6274305B1 (en) 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US7053190B2 (en) 1997-03-07 2006-05-30 Human Genome Sciences, Inc. Secreted protein HRGDF73
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6506569B1 (en) 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US5948609A (en) 1997-12-03 1999-09-07 Carter; Daniel C. Oxygen-transporting albumin-based blood replacement composition and blood volume expander
WO2000008207A1 (en) 1998-08-06 2000-02-17 Syntron Bioresearch, Inc. Uric acid assay device with stabilized uricase reagent composition
JP2002533134A (ja) 1998-12-23 2002-10-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ペプチドグリカン認識タンパク質
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
EP1179012B2 (en) 1999-05-17 2009-07-15 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
CA2371912C (en) 1999-05-21 2010-02-16 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DK1266006T3 (da) 2000-03-22 2006-01-16 Octagene Gmbh Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
EP1366077B1 (en) 2000-09-15 2011-05-25 Coley Pharmaceutical GmbH PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
WO2002055110A2 (en) 2000-10-25 2002-07-18 Genzyme Corp Methods for treating blood coagulation disorders
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
AUPR446701A0 (en) 2001-04-18 2001-05-17 Gene Stream Pty Ltd Transgenic mammals for pharmacological and toxicological studies
WO2002102830A1 (en) 2001-06-15 2002-12-27 New Century Pharmaceuticals, Inc. Human albumin animal models for drug evaluation, toxicology and immunogenicity studies
AUPR622301A0 (en) 2001-07-09 2001-08-02 Novapharm Research (Australia) Pty Ltd Infection control system
EP1421187B1 (en) 2001-07-27 2007-10-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Systems for in vivo site-directed mutagenesis using oligonucleotides
CN1405182A (zh) 2001-08-10 2003-03-26 中国人民解放军军事医学科学院生物工程研究所 血清白蛋白与粒细胞集落刺激因子的融合蛋白
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20060122374A1 (en) 2002-02-07 2006-06-08 Peter Mertins Albumin-fused anti-angiogenesis peptides
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US6995933B1 (en) 2002-04-30 2006-02-07 Western Digital Technologies, Inc. Disk drive for optimizing write current settings relative to drive operating characteristics and ambient temperature readings
WO2003102136A2 (en) 2002-05-30 2003-12-11 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
GB0217347D0 (en) 2002-07-26 2002-09-04 Univ Edinburgh Novel albumins
EP1572955A2 (en) 2002-08-02 2005-09-14 Human Genome Sciences, Inc. Antibodies against c3a receptor
EP1578254B1 (en) 2002-11-19 2013-03-06 DRG International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
JP2006518727A (ja) 2003-02-17 2006-08-17 アッパートン リミテッド キャリヤー、ターゲッティング部分、および造影剤を含んでいる医療用イメージングのための接合体
GB0305989D0 (en) 2003-03-15 2003-04-23 Delta Biotechnology Ltd Agent
WO2004082640A2 (en) 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
EP1618131A2 (en) 2003-04-15 2006-01-25 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
WO2004101620A2 (en) 2003-05-01 2004-11-25 Compound Therapeutics, Inc. Serum albumin scaffold-based proteins and uses thereof
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US6949961B2 (en) 2003-10-06 2005-09-27 Semiconductor Components Industries, L.L.C. Power switch structure with low RDSon and low current limit
WO2005082423A2 (en) 2003-11-18 2005-09-09 Beth Israel Deaconess Medical Center Serum albumin conjugated to fluorescent substances for imaging
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
CA2486245C (en) 2003-12-26 2013-01-08 Nipro Corporation Albumin having enhanced antimicrobial activity
JP4649954B2 (ja) 2003-12-26 2011-03-16 ニプロ株式会社 抗菌作用が増強されたアルブミン
KR100671005B1 (ko) 2004-01-15 2007-01-18 고려대학교 산학협력단 Ｐａｈ 노출 여부 진단용 바이오 마커 단백질
RU2369404C2 (ru) 2004-02-09 2009-10-10 Хьюман Дженом Сайенсиз, Инк. Слитые белки альбумина
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
JP4492156B2 (ja) 2004-03-03 2010-06-30 ニプロ株式会社 血清アルブミンドメインを含む蛋白質
US20060018859A1 (en) 2004-07-16 2006-01-26 Carter Daniel C Modified human serum albumin with reduced or eliminated affinity to chemical or biological contaminants at Cys 34
US20060051859A1 (en) 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
EP1831373A2 (en) 2004-12-22 2007-09-12 Novozymes A/S Recombinant production of serum albumin
EP2330200B1 (en) 2004-12-23 2017-04-05 Albumedix A/S Gene expression technique
WO2006073195A1 (ja) 2005-01-07 2006-07-13 Biomarker Science Co., Ltd 糖尿病の予知・診断方法および糖尿病予知・診断用キット
US20060178301A1 (en) 2005-02-04 2006-08-10 Mathias Jurs Albumin-fused ciliary neurotrophic factor
JP2008538919A (ja) 2005-04-29 2008-11-13 ザ ジャクソン ラボラトリー ＦｃＲｎ抗体およびその使用
GB0512707D0 (en) 2005-06-22 2005-07-27 Delta Biotechnology Ltd Gene expression technique
CA2618476A1 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
US8008257B2 (en) 2005-10-20 2011-08-30 University Of Ottawa Heart Institute ANF fusion proteins
AU2006329215A1 (en) 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
WO2007144173A1 (en) 2006-06-14 2007-12-21 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
CA2657277C (en) 2006-07-13 2015-11-24 Upperton Limited Process for preparing particles of proteinaceous material
JP4983148B2 (ja) 2006-08-18 2012-07-25 ニプロ株式会社 糖鎖含有アルブミン、その製造方法およびその用途
KR20090060294A (ko) 2006-09-08 2009-06-11 암브룩스, 인코포레이티드 변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
US20100129846A1 (en) 2006-12-07 2010-05-27 Power3 Medical Products, Inc. Isoform specificities of blood serum proteins and their use as differentially expressed protein biomarkers for diagnosis of breast cancer
EP2594583A1 (en) 2007-08-08 2013-05-22 Novozymes Biopharma DK A/S Transferrin variants and conugates
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
CA2611540C (en) 2007-11-09 2017-05-30 Nipro Corporation Sugar chain-containing albumin as a drug carrier to the liver
MX2010006735A (es) 2007-12-21 2010-09-30 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
EP2297182A4 (en) 2008-04-28 2012-08-15 Harvard College HIGHLY CHARGED PROTEINS USED FOR CELL PENETRATION
MX2011000655A (es) 2008-07-18 2011-03-21 Oragenics Inc Composiciones para la deteccion y tratamiento de cancer colorrectal.
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
CA2893696C (en) 2008-12-05 2018-09-04 Abraxis Bioscience, Llc Albumin binding peptide-mediated disease targeting
EP2370473B1 (en) 2008-12-10 2016-05-11 The Scripps Research Institute Production of carrier-peptide conjugates using chemically reactive unnatural amino acids
SG172789A1 (en) * 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
EP2414019B1 (en) 2009-04-02 2017-12-06 Breathe Technologies, Inc. Methods, systems and devices for non-invasive open ventilation with gas delivery nozzles in free space
WO2010118169A2 (en) 2009-04-08 2010-10-14 The Regents Of The University Of California Human protein scaffold with controlled serum pharmacokinetics
WO2010129023A2 (en) 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
WO2010138814A2 (en) 2009-05-29 2010-12-02 The Brigham And Women's Hospital, Inc. Disrupting fcrn-albumin interactions
EP2437767B1 (en) 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
EP2456454A4 (en) 2009-07-20 2013-03-20 Univ Nat Cheng Kung FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
WO2011044563A2 (en) 2009-10-10 2011-04-14 The Board Of Trustees Of The Leland Stanford Junior University Il-17 family cytokine compositions and uses
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
KR20120130752A (ko) 2009-12-23 2012-12-03 내셔널 타이완 유니버시티 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
CN101875693B (zh) 2010-01-22 2012-07-18 成都正能生物技术有限责任公司 具备抗血管生成活性的白蛋白变异体及其制备方法
WO2011103076A1 (en) 2010-02-16 2011-08-25 Medlmmune, Llc Hsa-related compositions and methods of use
KR20130070576A (ko) * 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
WO2011161127A1 (en) 2010-06-21 2011-12-29 Medimmune, Llc Protease variants of human neprilysin
EP2603522A1 (en) 2010-08-13 2013-06-19 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
WO2012059486A1 (en) 2010-11-01 2012-05-10 Novozymes Biopharma Dk A/S Albumin variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
EP2675471A4 (en) 2011-02-15 2015-01-28 Medimmune Llc HSA-RELATED COMPOSITIONS AND USE PROCESSES
WO2012150319A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
WO2014005596A1 (en) 2012-07-03 2014-01-09 Aarhus Universitet Modified payload molecules and their interactions and uses
US8757798B2 (en) 2012-08-31 2014-06-24 Cody Air LLC Eyewear frame
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
AU2014217831A1 (en) 2013-02-16 2015-07-16 Albumedix Ltd. Pharmacokinetic animal model
WO2014179657A1 (en) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
US20160222087A1 (en) 2013-09-13 2016-08-04 Novozymes Biopharma Dk A/S Albumin variants

Also Published As

Publication number Publication date
EP3330283A2 (en) 2018-06-06
ES2664328T3 (es) 2018-04-19
DK2825556T3 (en) 2018-04-16
EP2825556A1 (en) 2015-01-21
US10329340B2 (en) 2019-06-25
AU2017228726A1 (en) 2017-10-12
JP6657284B2 (ja) 2020-03-04
US20150065687A1 (en) 2015-03-05
WO2013135896A1 (en) 2013-09-19
US9944691B2 (en) 2018-04-17
CN104736559A (zh) 2015-06-24
PL2825556T3 (pl) 2018-10-31
IL233689A0 (en) 2014-09-30
AU2013234299A1 (en) 2014-08-14
EP3330283A3 (en) 2018-07-11
JP2015512893A (ja) 2015-04-30
JP2018138023A (ja) 2018-09-06
US20190315836A1 (en) 2019-10-17
AU2013234299B2 (en) 2017-06-22
JP6441682B2 (ja) 2018-12-19
KR20140136934A (ko) 2014-12-01
CN104736559B (zh) 2022-04-08
BR112014018679A2 (pt) 2017-07-04
EP2825556B1 (en) 2018-01-03
US20180265569A1 (en) 2018-09-20
CA2861592A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
MX2015005363A (es) Variantes de albumina.
EP3330283A3 (en) Albumin variants
MX353621B (es) Variantes de alfa-amilasa.
IN2014CN00597A (enExample)
MX351762B (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
MX351154B (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EP4477734A3 (en) Protease variants and polynucleotides encoding same
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
MX2014004539A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2014177546A3 (en) Glucoamylase variants and polynucleotides encoding same
MX352023B (es) Variantes de alfa-amilasa con estabilidad mejorada.
MX353710B (es) Polipeptidos que tienen actividad de lisozima y polinucleotidos que los codifican.
MX2013007997A (es) Polipeptidos que tienen actividad de incremento celulolitico y polinucleotidos que codifican para los mismos.
WO2012044915A3 (en) Beta-glucosidase variants and polynucleotides encoding same
MX2015000312A (es) Polipeptidos que tienen actividad lipasa y polinucleotidos que los codifican.
MX2021013104A (es) Variantes de lipasa y polinucleotidos que las codifican.
WO2014195356A3 (en) Alpha-amylase variants and polynucleotides encoding same
MX2015013447A (es) Polipeptidos que tienen actividad de la fosfolipasa a y polinucleotidos que los codifican.
WO2011109524A3 (en) Xylanase variants and polynucleotides encoding same
WO2013096603A3 (en) Cellobiohydrolase variants and polynucleotides encoding same
MX2014001594A (es) Polipeptidos que tienen actividad de celulasa y polinucleotidos que los codifican.
WO2014177541A3 (en) Glucoamylase variants and polynucleotides encoding same
MX349517B (es) Polipeptidos que tienen actividad de proteasa y polinucleotidos que codifican los mismos.
IN2014CN03187A (enExample)

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ARLANXEO DEUTSCHLAND GMBH

GB Transfer or rights

Owner name: ALBUMEDIX LTD

FG Grant or registration